X4 Pharmaceuticals (NASDAQ:XFOR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.
Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes. The company’s research and development pipeline also includes preclinical candidates exploring CXCR4 antagonism in inflammatory and fibrotic diseases.
Headquartered in Bedford, Massachusetts, X4 Pharmaceuticals conducts global clinical studies across North America and Europe, leveraging collaborations with leading academic centers and regulatory bodies to support its development efforts. The company’s infrastructure emphasizes translational science, streamlined operations, and patient-centric trial design to accelerate the advancement of its programs.
Publicly traded on the NASDAQ under the ticker XFOR, X4 Pharmaceuticals is dedicated to bringing innovative immunotherapeutics to underserved patient populations. Through strategic partnerships, regulatory engagement, and a focus on rare disease expertise, the company aims to deliver new treatment options that address significant unmet medical needs.
